5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital

Page 1 of 5

In this article, we discuss 5 pharmaceutical stocks to buy according to Lawrence Hawkins’ Prosight Capital. If you want to read our detailed analysis of Hawkins’ history, investment philosophy, and hedge fund performance, go directly to the 10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital.

5. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

Prosight Capital Stake Value: $6.7 million

 

Percentage of Prosight Capital’s 13F Portfolio: 4.21%

 

No. of Hedge Fund Holders: 18

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a biotechnology company based in Lexington, Massachusetts and it ranks fifth on the list of 10 pharmaceutical stocks to buy according to Lawrence Hawkins’ Prosight Capital. The company’s prime focus is to develop immune-modulating therapies for the treatment of ocular and systemic disorders. Reproxalap is the company’s principal product. In the second quarter of 2021, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) reported an EPS of -$0.28, missing estimates by $0.03.

Hawkins’ Prosight Capital owns 595,239 shares worth $6.7 million in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). This represents 4.21% of the total holdings of Prosight Capital. The hedge fund increased stake in the company by 26% during the second quarter of 2021 compared to the first quarter.

At the end of the second quarter of 2021, 18 hedge funds in the database of Insider Monkey held stakes worth $189 million in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), up from 17 the preceding quarter worth $153.9 million.

Page 1 of 5